Ballicules.com

Umeclidinium

INCRUSE

What it isLong-acting muscarinic antagonist; maintenance bronchodilation in COPD.

Why this oneIts once-daily Ellipta formulation simplifies COPD maintenance, but it has no asthma indication.

What limits itAnticholinergic effects can precipitate urinary retention or angle-closure glaucoma; it is never a rescue inhaler.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Maintenance treatment of COPDAdults62.5 mcg (1 actuation) QD inhaled62.5 mcg QD62.5 mcg QD

Renal No adjustment needed (including severe renal impairment)

Hepatic No adjustment for moderate impairment; severe not studied

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Insufficient human data; no adverse embryofetal effects in animals

Lactation No human data; detected in rat milk; weigh benefits/risks

NO BOXED WARNINGS

Principal riskAnticholinergic effects; acute urinary retention

Cost, est. cash$200–$900/month

Generic entry2030 est.

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism4 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilityTremor, tachycardia or anticholinergic effects; excessive beta-agonist exposure can cause hypokalemia and arrhythmia.

Mechanism of action: Umeclidinium ballicule

Umeclidinium ballicule: receptor binding, kinetics and half-life diagram

Open Umeclidinium in the interactive console ↗

Memory aids: mascots and interaction avatars

Umeclidinium INCRUSE ELLIPTA mascot mnemonic cartoon
“Ume the Euphonium (In cruise)”
“Red as a beet” crimson color theme → anticholinergic
Llama → long-acting muscarinic antagonist (LAMA)

Open Umeclidinium in the interactive console ↗